rifampin and Pulmonary-Aspergillosis

rifampin has been researched along with Pulmonary-Aspergillosis* in 1 studies

Other Studies

1 other study(ies) available for rifampin and Pulmonary-Aspergillosis

ArticleYear
Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1

    We investigated the effects of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis. Serum itraconazole concentrations were significantly lower in patients who received itraconazole with rifampin (median, 0.1 μg/ml; P < 0.001) or rifabutin (median, 0.34 μg/ml; P < 0.001) than those receiving itraconazole alone (median, 5.92 μg/ml). Concomitant use of rifampin or rifabutin and itraconazole should be avoided in patients with chronic pulmonary aspergillosis and coexisting mycobacterial infections.

    Topics: Aged; Antibiotics, Antitubercular; Antifungal Agents; Coinfection; Female; Humans; Itraconazole; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Pulmonary Aspergillosis; Retrospective Studies; Rifabutin; Rifampin

2015